Drugs / Oral Poliovirus Vaccine
Oral Poliovirus Vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT00130832 | Oct 2005 → Jul 2006 | Rotavirus infection, gastroenteritis | Merck Sharp & Dohme LLC | Completed | Mixed |
| Comparator or background therapy2 trials | ||||||
| Phase 3 | NCT01825109 Background | Jul 2010 → Apr 2011 | — | International Centre for Diarrhoeal Disease Research, Bangladesh | Completed | No outcome recorded |
| Phase 3 | NCT01021293 Comparator | Nov 2009 → Jul 2010 | poliomyelitis | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Oral Poliovirus Vaccine | “co-administered with oral polio virus vaccine” NCT01825109 ↗ |
| Known as | OPV | “received 3 doses of Oral Poliomyelitis Vaccine (OPV) at 2, 3 and 4 months of age, according to the vaccination policy recommended in China.” NCT01021293 ↗1“Comparator: Oral Poliovirus Vaccine (OPV)” NCT00130832 ↗ |
| Known as | Oral Poliomyelitis Vaccine (OPV) | “received 3 doses of Oral Poliomyelitis Vaccine (OPV) at 2, 3 and 4 months of age, according to the vaccination policy recommended in China.” NCT01021293 ↗ |
| Modality | Vaccine | “oral poliovirus vaccine (OPV)” NCT00130832 ↗ |
| Route | Oral | “Comparator: Oral Poliovirus Vaccine (OPV)” NCT00130832 ↗ |